Extended 10-Panel

The Extended 10-Panel covers the same five substances as the Core 5-Panel (CDT, cocaine, ketamine, amphetamines, and 3-MMC) and adds five additional substances: LSD, GHB, phenibut, 6-MAM (a heroin-specific metabolite), and opiates. This broader scope may be relevant when a wider range of substances is of interest.

Some of the additional substances have notably short detection windows. GHB, for example, may only be detectable in urine for approximately 8 to 12 hours after use, while 6-MAM (specific to heroin) has a window of approximately 2 to 8 hours. Timing of sample collection relative to last use is therefore particularly relevant for these substances.

This test may be relevant for:

• Individuals who wish to screen for a broader range of substances
• People who want a more extensive overview for personal or professional reasons
• Anyone seeking data on substances not covered by a standard 5-panel screening

The panel includes the following substances and metabolites:

• CDT (Carbohydrate-Deficient Transferrin): blood, expressed as %. Reflects consumption patterns over approximately two to four weeks.
• Cocaine metabolite (benzoylecgonine): urine. Detection window: approximately 2 to 4 days.
• Ketamine (norketamine): urine. Detection window: approximately 2 to 4 days.
• Amphetamines: urine. Detection window: approximately 2 to 4 days.
• 3-MMC: urine. Detection window: approximately 2 to 4 days.
• LSD: urine. Detection window: approximately 1 to 3 days.
• GHB: urine. Detection window: approximately 8 to 12 hours. This is a notably short window; timing of sample collection is particularly relevant.
• Phenibut: urine. Detection window: approximately 2 to 5 days.
• 6-MAM (heroin-specific metabolite): urine. Detection window: approximately 2 to 8 hours. Opiates may remain detectable longer.
• Opiates: urine. Detection window: approximately 2 to 4 days.

Each substance is reported as detected or not detected based on laboratory thresholds. A positive result indicates that the substance or its metabolite was found above the reporting threshold. A negative result means it was not detected at the time of collection.

Due to the very short detection windows of some substances (particularly GHB and 6-MAM), a negative result does not necessarily rule out recent use. Conversely, a positive result confirms detection but does not indicate quantity or frequency of use. If a substance is detected, confirmation testing may be performed to verify the finding.

This panel requires two types of samples, both collected at a certified sample point (afnamepunt):

• A blood draw for CDT analysis
• A urine sample (mid-stream) for all substance metabolite screening

The collection is carried out by trained personnel. Both samples are typically collected during the same visit.

This test may be considered when:

• A broader range of substances is relevant for the screening
• Insight into both longer-term patterns (via CDT) and recent use (via urine metabolites) is desired
• Substances with short detection windows (such as GHB or 6-MAM) are of interest, with the understanding that sample timing is particularly relevant

Results are presented per substance as detected or not detected. For CDT, the result is a percentage value, with elevated levels potentially indicating sustained alcohol consumption.

Given the varying detection windows across substances, interpretation should account for the timing of sample collection. For substances with very short windows (GHB, 6-MAM), a negative result may simply reflect that the detection window had passed. Results should be discussed with a healthcare provider for proper interpretation.

No specific preparation is required for the blood draw. For the urine sample, collect a mid-stream sample at the sample point. Hydrate normally beforehand; over-hydration may dilute the sample. If screening for substances with short detection windows (such as GHB), the timing of sample collection relative to suspected last use is particularly relevant.

Results are typically available within a few working days. The report provides a per-substance overview of findings.

If any substance is detected in the initial screening, confirmation testing using a more specific laboratory method may be performed. The final report includes the confirmed results. A healthcare provider can assist with interpreting the findings in context.